Medullary thyroid carcinoma, MEN2, pregnancy, severe gastroparesis, and other absolute and relative contraindications.
Overview
Safety considerations for GLP-1 receptor agonists fall into a few categories: predictable GI effects that resolve with titration, less common but more serious effects that warrant clinical attention, and very rare effects that have driven boxed warnings or formal contraindications.
Who is at higher risk
Patient-specific risk factors — including age, comorbidities, concurrent medications, and family history — change the safety calculus. The factors that matter for this specific concern are detailed below.
When to involve your clinician
For most safety concerns on GLP-1 therapy, an asynchronous message to your prescribing clinician within 24–48 hours is appropriate. For severe symptoms — severe pain, persistent vomiting, signs of allergic reaction, or symptoms suggesting pancreatitis — seek emergency care.
Our editor's pick for a clinician-supervised program
For ongoing GLP-1 management with built-in clinician access and lab monitoring, our top-ranked program is NexLife: MD/DO supervision, included labs, and message-based access to the clinical team.
Related safety guides
NexLife scored highest on our rubric (94/100) for rigorous safety oversight. Flat-rate pricing across full titration, labs included, MD/DO oversight, both 503A and 503B pharmacy partners.
This article was authored by Eduard Cristea and clinically reviewed by Dr. A. Goher, MD. Health Technology Researcher & Publisher. See our methodology and affiliate disclosure.